Paul Hamberg
Overview
Explore the profile of Paul Hamberg including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
85
Citations
1297
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Isebia K, de Jong A, van Dessel L, de Weerd V, Beaufort C, Helmijr J, et al.
Mol Oncol
. 2025 Mar;
PMID: 40084488
Cell-free circulating tumor DNA (ctDNA) has emerged as a promising biomarker for response evaluation in metastatic castration-resistant prostate cancer (mCRPC). The current study evaluated the modified fast aneuploidy screening test-sequencing...
2.
Staehler M, Basso U, Eymard J, Barthelemy P, Bigot P, Laramas M, et al.
Clin Genitourin Cancer
. 2024 Dec;
23(1):102285.
PMID: 39740313
Background: There is a lack of published data on real-world cabozantinib use in patients with advanced renal cell carcinoma after prior vascular endothelial growth factor (VEGF)-targeted therapy. Methods: CASSIOPE was...
3.
Beyoglu D, Hamberg P, IJzerman N, Mathijssen R, Idle J
Biomed Pharmacother
. 2024 Dec;
182():117773.
PMID: 39693904
Ifosfamide causes neurotoxicity, including sometimes fatal encephalopathy, in a small number of patients. Why and how this occurs is not fully understood. It is generally believed that N-dechloroethylation of ifosfamide...
4.
Figaroa O, Zondervan P, Kessels R, Berkhof J, Aarts M, Hamberg P, et al.
Eur Urol Open Sci
. 2024 Nov;
70:28-35.
PMID: 39483517
Background: Historically, patients with metastatic renal cell carcinoma (mRCC) have been offered upfront cytoreductive nephrectomy (CN) followed by systemic therapy. Currently, CN is no longer the standard of care (SOC)...
5.
Knikman J, Zhai Q, Lunenburg C, Henricks L, Bohringer S, van der Lee M, et al.
Genome Med
. 2024 Aug;
16(1):101.
PMID: 39148102
Background: The Alpe-DPD study (NCT02324452) demonstrated that prospective genotyping and dose-individualization using four alleles in DPYD (DPYD*2A/rs3918290, c.1236G > A/rs75017182, c.2846A > T/rs67376798 and c.1679 T > G/rs56038477) can mitigate...
6.
Meertens M, Giraud E, van der Kleij M, Westerdijk K, Guchelaar N, Bleckman R, et al.
Clin Pharmacokinet
. 2024 Jul;
63(7):1045-1054.
PMID: 39012619
Introduction And Objective: Pazopanib is registered for metastatic renal cell carcinoma and soft-tissue sarcoma (STS). Its variable pharmacokinetic (PK) characteristics and narrow therapeutic range provide a strong rationale for therapeutic...
7.
Boerrigter E, Overbeek J, Benoist G, Somford D, Hamberg P, Tol J, et al.
Eur Urol Oncol
. 2024 Mar;
7(6):1376-1383.
PMID: 38485614
Background And Objective: Enzalutamide is a potent androgen receptor signalling inhibitor, effectively used for the treatment of different stages of prostate cancer. Side effects occur frequently at the registered dose,...
8.
Rijnders M, Nakauma-Gonzalez J, Robbrecht D, Gil-Jimenez A, Balcioglu H, Oostvogels A, et al.
Nat Commun
. 2024 Feb;
15(1):1349.
PMID: 38355607
Immune checkpoint inhibitors (ICI) improve overall survival in patients with metastatic urothelial cancer (mUC), but therapeutic success at the individual patient level varies significantly. Here we identify predictive markers of...
9.
de Jong A, Isebia K, Ling S, de Weerd V, Van N, Kraan J, et al.
JCO Precis Oncol
. 2023 Dec;
7:e2300156.
PMID: 38061007
Purpose: Reliable biomarkers for response monitoring during radium-223 treatment in patients with metastatic castration-resistant prostate cancer (mCRPC) are lacking. Circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA), obtained from...
10.
Overbeek J, Guchelaar N, Mohmaed Ali M, Ottevanger P, Bloemendal H, Koolen S, et al.
Eur J Cancer
. 2023 Oct;
194:113346.
PMID: 37806255
Background: Pharmacokinetic (PK) boosting is the intentional use of a drug-drug interaction to enhance systemic drug exposure. PK boosting of olaparib, a CYP3A-substrate, has the potential to reduce PK variability...